A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating an investigational drug called "panobinostat" (LBH589) in
combination with the standard agents lenalidomide, bortezomib, and dexamethasone as a
possible treatment for multiple myeloma.